The AHA Guidelines and Scientific Statements Handbook

Index

Atrophy, peroneal muscular 285
Atropine 75, 77–8, 259
Auscultation 167
Autosomal recessive disease 238–9
AV
blocker 255, 257–8, 261, 263, 267–8, 282, 285, 290
conduction 285, 291
synchrony 71
AVNRT 255–7, 260–2
AVR 144, 297–302, 310
AVRT 256–8, 264
Azimilide 263
Azithromycin 335

B-type natriuretic peptide 226
Bacilli, aerobic gram-negative 329
Bacteremia 332–4
persistent 309–10
staphylococcal 309
Ballooning, apical 242
Barorefl ex 274
Barth syndrome 241
Bartonella 328
Basic life support 104
Benazepril 227
Bepridil 290
Beriberi 241
Beta-myosin 238
Betaxolol 227
Beta blocker
oral 209
vasodilating 213
Beta-adrenergic blocker 192, 231
Bilevel positive airway pressure 66
Biomarkers 53–4, 276, 291
cardiac 139, 276
serial 53
release of, after acute MI 26
Bioprosthesis 310–1
Biopsy, endomyocardial 225–6
Bisoprolol 206, 209, 227
Bivalirudin 26, 34–5, 37, 45, 63, 117, 127, 131–2
Bleeding, gastrointestinal 35, 216
Block, atrioventricular 272
Blockade
aldosterone 70, 111, 114–5, 220
beta-adrenergic 74–5
beta-adrenoceptor 73
nodal 291
sequential nephron 228
Blocker-related toxicity 291
Blood pressure. See BP
BMI 202–3, 217–8, 225

Body mass index. See BMI

Boston Area Anticoagulation Trial for Atrial Fibrillation

247

BP 167, 174–6, 193, 216–7, 219

abnormal exercise 285

ambulatory 201

control 200–2, 204, 206, 209–10

and CVD 199

goal 200, 202, 207–8

levels 197–8

lowering 200, 206, 209, 212–3

treatment 196–213

Brachytherapy 132

Brachytherapy, vascular, versus repeat balloon expansion

129

Bradyarrhythmia 75, 78, 208, 275

Bradycardia 17, 34, 54, 67, 71, 73, 75, 77, 160, 163, 204,

247, 262, 277, 282

Brugada syndrome 239, 287, 291

Bruits 167, 202

Buerger’s disease 169

Bumetanide 70, 228

Bupropion 141, 175

Butilide 267

Bypass

aortobifemoral 179–80, 183

axillofemoral-femoral 179–80, 183

distal 185

femoral-femoral 180, 183

femoral-popliteal 172

femoral-tibial 170, 172, 180, 185

femoropopliteal-tibial 185

graft 181, 184–5

iliofemoral 180, 183

lower extremity 181, 185

operative 181

surgery

aortocoronary 120

coronary 128

surgical 172, 177

Bypass Angioplasty Revascularization Investigation 143,

145

CABG 39, 40–1, 52–3, 59–61, 63, 68–71, 73, 78–81, 92,

104, 121–4, 135–51, 216, 297–8, 300, 308

concomitant 144

cost effi ciency of 134, 146

emergency 126, 138, 149

ischemic mitral regurgitation 308

mortality 135, 149

vs. PCI 347–8

prior 150–1

vs. PTCA 135